CLINICAL TRIAL NEWS
Here you will find news and webinars related to Huntington Disease clinical trials and studies.
2025
October 24th, 2025
Community Update:
October 10th, 2025
Community Update:
We break down the new AMT-130 results — what the data shows, why it matters, and what this could mean for the future of Huntington’s disease research.
September 24th, 2025
Positive news for the HD Community!
uniQure announced today the results for the Phase I/II Study of AMT-130 for the treatment of patients with HD. The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months compared to a propensity score-matched external control.
September 18th, 2025
Promising Results for New HD Drug SKY-0515
Skyhawk Therapeutics has shared encouraging early trial results for SKY-0515, an experimental pill being studied for Huntington’s disease. The drug reached the brain well, was safe so far, and is now moving into a larger Phase 2/3 trial with 120 participants in Australia and New Zealand.
September 3rd, 2025
Learning from Sweden's Multidisciplinary HD Care
During our annual team meeting in Sweden, we visited the HD Clinic at Skåne University Hospital, in Lund.
We met Professor Åsa Petersén and nurse Camilla Svensson, and saw firsthand how their multidisciplinary team combines research with compassionate care ![]()
August 28th, 2025
Simplifying Science: What Causes Huntington's Disease?
In this new series, we want to take a deep dive into scientific concepts in a simple way, with the goal of eventually bringing research concepts closer to all of you.
This first article will be dedicated to understanding the hereditary nature of HD.
We hope this information explains well most of the aspects of the genetic and hereditary nature of HD. Stay tuned because in our next article we will keep simplifying science and taking a closer look at the neurodegenerative process!
August 21st, 2025
Novartis is planning a phase 3 trial of Votoplam
July 25th, 2025
Prilenia and Ferrer provide update on European regulatory process for Pridopidine in Huntington's Disease
May 6th, 2025
PTC Press Release Explained: What It Means for Our Community | May 2025 Update
Astri Arnesen and Dina de Sousa take a closer look at PTC Therapeutics’ press release, highlighting what the latest updates mean for people affected by Huntington’s disease.
In this video, they explain the main findings in a way that’s easy to follow and emphasize why this development brings hope to the community.
It’s a great starting point for understanding the news — and we encourage everyone to read the full press release for all the scientific details.
May 5th, 2025
PTC518 PIVOT-HD Study Achieves Primary Endpoint
Big news from PTC Therapeutics! PTC has announced important updates on their investigational treatment for Huntington’s Disease, paving the way for next steps in clinical development.
April 29th, 2025
PRILENIA AND FERRER PARTNER TO ADVANCE PRIDOPIDINE IN EUROPE AND SELECT MARKETS
Prilenia has entered into a significant collaboration with Ferrer to commercialize and further develop pridopidine in Europe and select markets. Pridopidine is a potent and highly selective orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD.
April 17th, 2025
uniQure’s Gene Therapy for Huntington’s Disease Receives Special FDA Designation
The FDA has granted Breakthrough Therapy Designation to uniQure’s gene therapy, AMT-130, for Huntington’s disease. This means the data so far looks very promising, and the therapy will now have faster access to review when full results are available. A hopeful step forward for the HD community!
April 17th, 2025
UPDATE ON THE PHASE II GENERATION HD2 STUDY
Roche has provided an interim update on the Phase II GENERATION HD2 clinical trial, which is evaluating the investigational drug tominersen in individuals with early or very subtle signs of HD. Read the full article to learn more
February 6th, 2025
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating
2024
December 10th, 2024
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
November 12th, 2024
FDA SHOWS INITIAL SUPPORT FOR WVE-003
This morning, Wave Life Sciences reported that they have received supportive initial feedback from FDA on WVE-003. They engaged the FDA following their positive SELECT-HD clinical results, and today, they announced that the FDA recognize the severity of HD and have indicated they are open to our plan to evaluate biomarkers, including caudate atrophy, as an endpoint to assess HD progression with the potential to predict clinical outcomes. FDA also granted WVE-003 Orphan Drug Designation last week.
Wave is now planning activities for an efficient global, potentially registrational Phase 2/3 study of WVE-003 and planning for an Investigational New Drug submission for this study in the second half of 2025.
October 30th, 2024
Webinar: Research Insights: Latest Updates on Ongoing Studies
On October 23rd, the European Huntington Association held an engaging and informative webinar titled “Research Insights: Latest Updates on Ongoing Studies.”
The webinar provided a comprehensive overview of the latest developments in clinical trials, with each company sharing updates and preliminary insights from their ongoing or completed studies in HD treatment.
These presentations underscored the diversity of approaches and the progress being made across therapeutic areas.
September 26th, 2024
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
July 9th, 2024
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
June 25th, 2024
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
June 20th, 2024
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
June 3rd, 2024
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
🙌Uniqure’s gene therapy for Huntington’s Disease, named AMT-130 has passed a significant next step.
The company announced that the US regulators, FDA, has granted them a Regenerative Medicine Advanced Therapy (RMAT) designation.
March 12th, 2024
NEW WEBINAR VIDEO AVAILABLE: Prilenia filing for EMA approval for Pridopidine - What does this mean for patients?
Watch our webinar with Henk Schuring, Chief Regulatory and Commercialization Officer at Prilenia, and Anne Rosser, Professor at Cardiff University, where we had the opportunity to better understand what Prilenia’s request for EMA’s (European Medicines Agency) approval of Pridopidine means for the Huntington’s Disease community.
March 12th, 2024
Prilenia will ask for market approval at the European Medicines Agency for Pridopidine (an oral drug) in Huntington’s Disease.
Today, Prilenia made a groundbreaking announcement, revealing that they are going to apply for market authorization at the European Medicines Agency (EMA) within the next few months. 💪This marks a historic moment as the first-ever medicine for Huntington’s Disease (HD) reaches this critical stage.
🙌 We think this is a day to celebrate. However, we fully realise this is not the end of the journey. submitting an application to the EMA and the review process takes time, and can have both a positive or a negative output. In collaboration with Prilenia we are organizing a Webinar, to provide us all with a more in-depth understanding of the rationale behind the decision to apply for market approval and what it means for patients.
January 9th, 2024
Watch now the Webinar video: Why do we need a second Generation HD trial?
The European Huntington Association, in collaboration with Roche, organized a webinar on January 9th to discuss the updates on the GENERATION HD2 clinical trial and address all the questions about why this trial is needed.
With 70 trial sites activated worldwide and over 30% of the trial enrolment, GENERATION HD2 clinical trial is on the right path. But we need to speed up to have the trial fully recruited as soon as possible to get the results. The trial aims to explore the effect on biomarkers and function in the 300 participants, all in early phases of HD and in the age between 25 and 50.
Listen to Professor Sarah Tabrizi (UCL) and Doctor Peter McColgan (MD PhD) from Roche talking about the latest updates on GENERATION HD2 trial.
2023
November 29th, 2023
Webinar for the nordic countries: HS forskningsoppdateringer for de nordiske landene
On the 22nd of November, the European Huntington Association and the Moving Forward team, in collaboration with the Norwegian HD Association and the Swedish HD Association, organized a Webinar on HD research updates for the Nordic Countries. The webinar is in Norwegian.
There were just over 70 participants from Norway, Sweden, Denmark, and Finland.
We were joined by Astri Arnesen, Lasse Pihlstrøm and Åsa Petersen to talk about what is happening in HD research globally and what is happening specifically in Norway and Sweden.
June 21st, 2023
uniQure Announces Update on AMT-130 study for the Treatment of Huntington’s Disease
The treatment tested in the AMT130 trial is well tolerated and Patients treated with AMT-130 show preserved function compared to when they started in the trial (baseline) and clinical benefits relative to the natural history of the disease. These are some of the results announced by UniQure in a press release.
In essence, this means that there are signs that the treatment works and slow down the progression of the disease. UniQure is re-encouraged by the results and plans to continue and extend the program
June 9th, 2023
2023 Community Survey - Understanding The Needs Of Young People Impacted By HD
The ultimate goal of this survey is to learn how the HDYO can meet these needs, so that it can support, educate and empower the young people from HD families across the globe. Thus, the results of this study will provide understanding about the needs of people impacted by HD and inform the types of support provided by HDYO.
June 9th, 2023
JOIN-HD – The Global Registry for Juvenile onset Huntington’s Disease
JOIN-HD is a worldwide registry for families affected by Juvenile onset Huntington’s Disease (JoHD), which aims to shed light on this diagnosis, bring together those impacted by JoHD, increase awareness and knowledge about this condition, facilitate research and help advocate for better care.
May 12th, 2023
WEBINAR VIDEO 🟢 PROOF-HD study good and less good news
On April 25th, Prilenia announced results from the PROOF-HD clinical trial for Huntington’s Disease. Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all.
The European Huntington Association, in collaboration with Prilenia, organized a Webinar to talk about the preliminary study results from the phase 3 PROOF-HD study and what they mean.
Listen to Dr Michael Hayden (founder and CEO of Prilenia), Dr Ralf Reilman (Principal Investigator for PROOF-HD in Europe) and Dr. Andrew Feigin (Chair at The Huntington Study Group) explaining the results and indicating further steps.
May 11th, 2023
There has been an amendment to the PIVOT HD trial entry criteria
We just updated the inclusion criteria for PIVOT HD, the PTC Therapeutics Phase II clinical trial.
- Length of trial from 12 weeks to 12 months
- CAG repeat length was previously 42-50 and is now 40-50
- Number of subjects was previously 162 an is now up to 252
- We are recruiting Stage II AND Stage 3 now (so TFC and/or Independence scale less than 13/100)
April 25th, 2023
Prilenia announce results from the PROOF-HD study
Prilenia announce results from the PROOF-HD study: Promising, but mixed results!
Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all. This is promising because, for the first time, we have a drug that demonstrates effect on disease progression, cognitive and motor symptoms.
After the announcement, the European Huntington Association organized a Webinar with Dr Michael Hayden, founder and CEO of Prilenia, who will explain the results and indicate further steps.
March 20th, 2023
WEBINAR VIDEO: Novartis Discusses the VIBRANT-HD Trial
The European Huntington Association, in collaboration with Novartis, organized a Webinar to learn more about VIBRANT-HD trial and the decision to stop the development of branaplam in Huntington’s Disease.
The webinar speakers included VIBRANT-HD clinical site investigator and Steering Committee member, Bernhart Landwehrmeyer, Medical lead for the branaplam program, Dr. Harry Ramos, and Clinical program head for the branaplam program, Dr. Beth Borowsky.
January 19th, 2023
WEBINAR: Updates of Wave's clinical trial SELECT-HD
The European Huntington Association, in collaboration with Wave, organized a Webinar on the updates of Select-HD clinical trial for Huntington’s disease.
Dr. Ralf Reilmann, founder of the George-Huntington Institute in Muenster, presented an overview of the SELECT-HD trial, which is looking at the safety of the investigational molecule called WVE-003. After his presentation, we had a Q&A session with Danlin Xu, HD Medical Director at Wave, and Marissa Volpe, HD Program Lead at Wave.
January 12th, 2023
WEBINAR: Updates from Roche on Phase II GENERATION HD2 study for Huntinton's Disease
The GENERATION HD2 clinical trial is just about to start recruiting participants in the first of a total of 15 countries and 9 of them are in Europe: Denmark, France, Germany, UK, Poland, Italy, Spain, Portugal and Switzerland. The study aims to enroll 360 participants and evaluate the safety of the investigational drug tominersen in people with early manifest HD.
January 11th, 2023
EFNA's new eLearning initiative on research
The online course aims to upskill participants on how they can effectively advocate in a virtual world by identifying and engaging key stakeholders and developing partnerships, hosting successful online events and developing and disseminating key advocacy messages.
December 16th, 2022
Updates from SOM Biotech
We met with Dr Catherine Scart, Chief Medical Officer at Som Biotech, and we asked her some questions about the new Phase 2b trial for Huntington’s Disease (HD) called SOM3355.
2022
December 12th, 2022
We moved VIBRANT-HD to the completed trials section
Novartis ends the VIBRANT-HD study and will not continue the program with Branaplam.
December 11th, 2022
Check our new Webinar section!
We have compiled all the European Huntington Association recent webinars in a new section that you can find in the menu of the webpage.
December 11th, 2022
We have adapted the HDTrial Finder dictionary to make it easier and more convenient by including it on the different clinical trial pages. Simply click on the highlighted words to find an easy definition.




